Menu
Peptide Database
Results
No peptides found
Featured

Use search to browse all 100+ peptides

LL-37

Cathelicidin, hCAP-18, FALL-39, CAP-18

Quick Stats
Studies 2230
Trials 95
Score 1
2020 pubmed 9 citations

Diminished Systemic and Mycobacterial Antigen Specific Anti-microbial Peptide Responses in Low Body Mass Index-Latent Tuberculosis Co-morbidity.

Rajamanickam. Anuradha A; Munisankar. Saravanan S; Dolla. Chandra Kumar CK; Babu. Subash S

Key Findings

  • Low BMI individuals with latent TB show reduced systemic levels of LL‑37 and other antimicrobial peptides
  • Both unstimulated and TB‑antigen‑stimulated levels of several AMPs are lower in low‑BMI subjects
  • Some antimicrobial peptide levels positively correlate with body‑mass index

Practical Outcomes

  • Maintaining a healthy body weight may help keep innate immune defenses, including antimicrobial peptides, at optimal levels. No specific LL‑37 supplementation or protocol is suggested by this study for longevity or performance purposes.

Summary

People with low body weight who have hidden TB infection have lower levels of natural antimicrobial proteins like LL‑37, HNP1‑3, granulysin and HBD‑2 in their blood, which may make it easier for the infection to become active disease.

Abstract

Low body mass index (BMI) is a risk factor for progression from latent <i>Mycobacterium tuberculosis</i> infection to active tuberculosis (TB) disease. Anti-microbial peptides (AMPs) are multifunctional molecules that play a crucial role in the mammalian host innate defense mechanism. AMPs have been shown to have an important role in host immunity to TB infection. The association of antimicrobial peptides with low BMI-latent tuberculosis (LTBI) co-morbidity has not been explored. To study the association of AMPs with LTBI-BMI, we examined the systemic, baseline, and mycobacterial antigen stimulated levels of human neutrophil peptides 1-3, (HNP1-3), granulysin, human beta defensin-2 (HBD-2), and cathelicidin (LL-37) in individuals with LTBI and low BMI (LBMI) and compared them with individuals with LTBI and normal BMI (NBMI). LBMI was characterized by diminished systemic levels of HNP1-3, granulysin, HBD-2 and cathelicidin in comparison with NBMI. Similarly, LBMI was also characterized by diminished unstimulated levels of HNP1-3 and granulysin and diminished mycobacterial antigen stimulated levels of HNP1-3, granulysin, and HBD-2. In addition, certain AMPs exhibited a positive correlation with BMI. Our data, therefore, demonstrates that coexistent LBMI in LTBI is characterized by the diminished levels of HNP1-3, granulysin, HBD-2, and cathelicidin, thereby potentially increasing the risk of progression to active TB.

Study Information

Provider

pubmed

Year

2020

Date

2020-04-28T00:00:00.000Z

DOI

10.3389/fcimb.2020.00165

Citations

9

References

47